Clinical trials · Washington, D.C., DC
Breast cancer clinical trials in Washington, D.C.
We’re tracking 163 recruiting breast cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Fairfax, VirginiaAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Fairfax, VirginiaAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Fairfax, VirginiaAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
Fairfax, VirginiaAges 18 years+ - NCT07524855RecruitingPhase 1
HLD-0117 study for metastatic breast cancer
This early-stage study tests a new drug called HLD-0117 in women whose metastatic breast cancer (cancer that has spread beyond the breast) has stopped responding to previous hormone and targeted therapies. The goal is to see if this drug can slow or shrink the cancer in patients who have limited options left.
Fairfax, VirginiaAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Fairfax, VirginiaAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Fairfax, VirginiaAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Fairfax, VirginiaAges 18 years+ - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Fairfax, VirginiaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Fairfax, VirginiaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Fairfax, VirginiaAges 18 years+ - NCT05856773RecruitingPhase 3
Standard vs shorter radiation to lymph nodes for breast cancer
This trial compares two ways of giving radiation to the breast/chest wall and nearby lymph nodes after breast surgery: a standard schedule versus a shorter “hypofractionated” schedule. It uses proton therapy and may help reduce treatment time while still controlling the cancer.
Fairfax, VirginiaAges 19 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Fairfax, VirginiaAges 18 years+ - NCT01766297RecruitingPhase 2
Proton radiation after lumpectomy for early breast cancer
This trial studies a type of radiation made with protons to treat only part of the breast after surgery (lumpectomy) for early-stage breast cancer. It may help control the cancer while aiming to reduce radiation to surrounding tissues.
Fairfax, VirginiaAges 50 years+ - NCT07287098RecruitingPhase 2
Imlunestrant for premenopausal women with ER+/HER2- early breast cancer
This trial tests a new hormone-blocking pill (imlunestrant) in premenopausal women with early-stage ER+/HER2- breast cancer. Depending on whether you've had prior hormone therapy, the study will see if this treatment works better than standard options.
Fairfax, VirginiaAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Fairfax, VirginiaAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Fairfax, VirginiaAges 12 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Fairfax, VirginiaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Fairfax, VirginiaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Fairfax, VirginiaAges 18 years+
Hear when a new Breast cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Breast cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting breast cancer studies listed above.
- NEXT Oncology · 12 studies
- Virginia Cancer Specialists · 7 studies
- Inova Schar Cancer Institute · 4 studies
- Maryland Proton Treatment Center · 2 studies
- Inova
- Investigative Site #112
- Johns Hopkins University
- Maryland Oncology Hematology
What taking part in a breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting breast cancer studies in District of Columbia.
Common questions
- Are there breast cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 163 recruiting breast cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.